1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma-Reference-Cited by-同舟云学术

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

Published:2009-05-18 Issue:1 Volume:45 Page:117-121
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Chang H,Qi X,Jiang A,Xu W,Young T,Reece D

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2009107.pdf

Reference21 articles.

1. Sawyer JR, Waldron JA, Jagannath S, Barlogie B . Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41–49.

2. Debes-Marun CS, Deqald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427–436.

3. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michalli J, Jhanwar SC et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91: 3007–3010.

4. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006; 108: 1733–1734.

5. Marzin Y, Jamet D, Douet-Guilbert N, Morel F, Le Bris M, Morice P et al. Chromosome 1 abnormalities in multiple myeloma. Anticancer Res 2006; 26: 953–960.

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Targeted Panel of 282 Genes: Unveiling Key Biomarkers in Multiple Myeloma;2023-11-01

2. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities;Leukemia & Lymphoma;2023-06-10

3. Making a case for del(1p) as a high‐risk abnormality in multiple myeloma;Cancer;2023-06-06

4. Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma;Haematologica;2022-09-29

5. Genomics of Plasma Cell Leukemia;Cancers;2022-03-21